1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Problems not over for Ranbaxy as FDA issues new import alert

 
• By Anju Ghangurde

Months after putting forth a robust defence suggesting there were "no remnants" of past practices that led to it pay $500m towards settling an investigation by the US Department of Justice concerning data integrity and manufacturing processes at two of its Indian sites, Ranbaxy Laboratories finds itself under the regulatory spotlight yet again.

Months after putting forth a robust defence suggesting there were "no remnants" of past practices that led to it pay $500m towards settling an investigation by the US Department of Justice concerning data integrity and manufacturing processes at two of its Indian sites, Ranbaxy Laboratories finds itself under the regulatory spotlight yet again.

This time, the US FDA has issued an import alert against its Mohali facility, the firm's third Indian site to be pulled up in addition to the Paonta Sahib and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

 
• By Dave Wallace

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.